Jing Yuan Ph.D.,

Clinical Pharmacy and Drug Administration

 >>About
 
 >>Faculty & Staff
 
 >>Degree Programs
 
 >>Research & Achievements
 
 >>Outstanding Students
 
 >>Exchange & Collaborations

Faculty & Staff

Jing Yuan Ph.D.,

2021/09/24 18:22:03

Personal information

Jing Yuan, Ph.D. B.Pharm
Youth Principle Investigator
Email: jyuan@fudan.edu.cn
Phone: 021-51980025
Address: 826 Zhangheng Rd, Shanghai 201203, China

Dr. Jing Yuanreceived her Ph.D. in Pharmaceutical and Health Outcomes Sciences with aconcentration on Pharmacoeconomics from the University of South Carolina in2018. Dr. Yuan has extensive experience in both academia and industry; she wasthe Assistant Professor at Rutgers University, she also worked at the bigmultinational pharmaceutical companies, such as Novartis and Johnson &Johnson. As a pharmacist by training, she is motivated to improve patient’s healthoutcomes and access to care, and her research therefore focuses oninvestigating the health outcomes and economic burdens associated with pharmaceuticalsor health services in the real-world.Her multidisciplinary research involveshealth outcomes research, health economics, epidemiology, and health policy.She also applied innovative analytical methods to address methodological issuesin the observational studies using big data. She has led and participatedresearch projects funded by NIH and CDC. She has authored two book chapters,published several peer-reviewed articles, and received multiple awards frominternational conferences, including Academy of Managed Care Pharmacy (AMCP), InternationalSociety for Pharmacoeconomics and Outcomes Research (ISPOR), and DrugInformation Association (DIA).

Keywords of research interests

Healtheconomics and outcomes research

Pharmacoepidemiology

Real-worldevidence

Evidence-basedmedicine

Pharmacypractice

Curriculum Vitae

Education

2011/08–2018/05 University Of South Carolina, Ph.D.

1996/09–2000/07 Tianjin Medical University, B.S.

ProfessionalExperiences

2020/08–present Fudan University, Youth Principle Investigator

2019/02–2020/07 Rutgers University, Assistant Professor

2018/08–2019/02 Ethicon, Johnson & Johnson Co, Ltd., DataScientist II

2017/10–2018/08 Novartis pharmaceuticals Co, Ltd., HE&ORPost-Doctoral fellow

2017/06–2017/08 Xcenda LLC, Real-world evidence summerintern

2005/06–2007/04 Sanofi-Aventis Beijing Co, Ltd., QC analyst

2004/06–2005/05 Novartis Beijing Pharmaceuticals Co, Ltd., QCanalyst

2001/01–2004/05 GlaxoSmithKline Tianjin Pharmaceuticals Co, Ltd.,QC analyst

2000/07–2001/01 Tianjin Hongri Pharmaceuticals Co, Ltd., QCanalyst

Grants& Projects

1. National Institutes of Health(NIH). “Feasibility Study of Incorporating Economic Analysis into EnvironmentalHealth Research”, 2019/07–2020/07,PI.

2. National Institutes of Health(NIH). “Reducing Agitation in People with Dementia: The Customized Activity Trial(TAP)”, 2019/02–2020/04,Participate.

3. U.S. Centers for Disease Controland Prevention (CDC). “Wills Eye Community Intervention to Improve GlaucomaDetection and Follow-Up Care”, 2019/02–2020/04,Participate.

Awards& Honors

1. 2019. International Society forPharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual InternationalMeeting, Poster Finalist Award, USA.

2. 2018. Academy of Managed CarePharmacy (AMCP) 2018 Annual Meeting, Silver Medal Award, USA.

3. 2015. International Society for Pharmacoeconomicsand Outcomes Research (ISPOR) 20th Annual International Meeting, PosterFinalist Award, USA.

4. 2014. Drug Information Association(DIA) 50th Annual Meeting, Student Poster Travel Award, USA, 2019.

5. 2014.InternationalSociety for Pharmacoeconomics and Outcomes Research (ISPOR) 6th Asia-PacificConferences, Student Poster Travel Award, China.

Memberships

Academyof Managed Care Pharmacy (AMCP)

InternationalSociety for Pharmacoeconomics and Outcomes Research (ISPOR)

DrugInformation Association (DIA)

InvitedPresentations

1. TAP Intervention Costs: Opportunities forStreamlining Delivery and Pursuing Reimbursement. The Gerontological Society ofAmerica's 2019 Annual Scientific Meeting, 2019

2. Effects of Medication Adherence among MedicareCancer Survivors. International Society for Pharmacoeconomics and OutcomesResearch (ISPOR) International meeting. 2017

SelectedPublications（latest5 yrs，<20papers）

1. Lu ZK, Yuan J, Li MH. Research Design and DataAnalysis. Pharmacoeconomics. Beijing: Capital Medical University Press. 2017.

2. Yuan J, Pizzi LT. Chapter 47. Value-Based PaymentModels Involving Pharmaceutical Care. The Remington: The Science and Practiceof Pharmacy. 23rd Edition.

3. Yuan J, Li MH, Lv Gang, Lu ZK. MonitoringTransmissibility and Mortality of COVID-19 in Europe. Int J Infect Dis. 2020Jun; 95:311-315.

4. Li MH, Lu ZK, Amrol DJ, Mann JR, Hardin JW, Yuan J,Cox C. Antibiotic Exposure and the Risk of Food Allergy: Evidence on HealthOutcomes in the U.S. Medicaid Pediatric Population. J Allergy Clin ImmunolPract. 2019;7(2):492-499.

5. Yuan J, Lu ZK, Zhang YJ, Wu J, Love BL, Schulz RM.Clinical Outcomes of Levalbuterol versus Racemic Albuterol in PediatricPatients with Asthma: A Retrospective Cohort Study in a High-risk, Low-incomePopulation. Pediatr Pulmonol. 2017;52(4):516-523.

6. Lu ZK, Li M, Phillips C?, McGee K, Yuan J, SuttonSS. The Impact of Dementia on Anti-Diabetic Drug Use in Medicare Beneficiarieswith Diabetes: Findings post-Medicare Part D. J Comp Eff Res. 2016;5(4):383-92.

7. Lu ZK, Li MH, Yuan J, Wu J. The Role ofCerebrovascular Disease and the Association between Diabetes Mellitus andDementia among Aged Medicare Beneficiaries. Int J Geriatr Psychiatry.2016;31(1):92-8.

8. ZK, Yuan J, Li MH, Sutton SS, Rao GA, Jacob S,Bennett CL. Cardiac Risks Associated with Antibiotics: Azithromycin andLevofloxacin. Expert Opin Drug Saf. 2015;14(2):295-303.